U.S. Rozanolixizumab (Rystiggo) Market Summary
The U.S. Rozanolixizumab (Rystiggo) market size was estimated at USD 199.13 million in 2024 and is expected to grow at a CAGR of 7.30% from 2025 to 2033. The U.S. Rozanolixizumab (Rystiggo) market focuses on treating generalized myasthenia gravis (gMG) in adults with anti-AChR or anti-MuSK antibodies. Growth is driven by demand for targeted biologics, supported by U.S. healthcare infrastructure and reimbursement policies.
The U.S. Rozanolixizumab (Rystiggo) market benefits from the drug’s FDA approval in June 2023 for gMG treatment. Growth is propelled by rising gMG diagnoses, estimated at 3.2 per 100,000 U.S. adults for the MG cases, and increasing demand for biologics targeting autoimmune disorders. UCB Pharma’s focus on subcutaneous administration enhances patient convenience, supporting market expansion. Projections to USD 732.98 million by 3033 reflect a steady CAGR of 7.30%, driven by ongoing clinical advancements and healthcare investments.
Rozanolixizumab (Rystiggo) stands out due to its mechanism of action, reducing IgG levels via FcRn inhibition, offering a novel approach compared to traditional immunosuppressants. Its approval for both anti-AChR and anti-MuSK antibody-positive patients broadens its market scope. Competitive advantages include fewer side effects and flexible dosing, positioning it favorably against alternatives such as efgartigimod. UCB’s marketing efforts emphasize these benefits, targeting neurologists and specialty clinics.
Emerging innovations include trials for additional indications, such as chronic inflammatory demyelinating polyneuropathy (CIDP), which could expand the market beyond gMG. The U.S. leads due to its research infrastructure, with clinical trial data from 2024 suggesting broader applications by 2027. Distribution enhancements via specialty pharmacies and e-commerce platforms further support growth, aligning with patient access trends.
U.S. Rozanolixizumab (Rystiggo) Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. Rozanolixizumab (Rystiggo) market report based on indication and distribution channel:
- Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Generalized Myasthenia Gravis (gMG)
- Emerging Pipeline Applications
- Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Hospital & Specialty Pharmacies
- Retail & E Commerce
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Indication
- 1.2.2. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR’s Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. U.S. Rozanolixizumab (Rystiggo) Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter’s Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- Chapter 4. U.S. Rozanolixizumab (Rystiggo) Market: Indication Business Analysis
- 4.1. Indication Market Share, 2024 & 2033
- 4.2. Indication Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
- 4.4. Generalized Myasthenia Gravis (gMG)
- 4.4.1. Generalized Myasthenia Gravis (gMG) Market, 2021 - 2033 (USD Million)
- 4.5. Emerging Pipeline Applications
- 4.5.1. Emerging Pipeline Applications Market, 2021 - 2033 (USD Million)
- Chapter 5. U.S. Rozanolixizumab (Rystiggo) Market: Distribution Channel Business Analysis
- 5.1. Distribution Channel Market Share, 2024 & 2033
- 5.2. Distribution Channel Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
- 5.4. Hospital & Specialty Pharmacies
- 5.4.1. Hospital & Specialty Pharmacies Market, 2021 - 2033 (USD Million)
- 5.5. Retail & E‑Commerce
- 5.5.1. Retail & E‑Commerce Market, 2021 - 2033 (USD Million)
- Chapter 6. Competitive Landscape
- 6.1. Participant Overview
- 6.2. Company Market Position Analysis
- 6.3. Company Categorization
- 6.4. Strategy Mapping
- 6.5. Company Profiles/Listing
- 6.5.1. UCB
- 6.5.1.1. Overview
- 6.5.1.2. Financial Performance
- 6.5.1.3. Product Benchmarking
- 6.5.1.4. Strategic Initiatives
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook